

AD _____

Award Number: W81XWH-06-1-0049

TITLE: TSC2 Haploinsufficiency Leads to a Mutator Phenotype

PRINCIPAL INVESTIGATOR: Cheryl Walker, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas
M.D. Anderson Cancer Center
Houston, TX 77030

REPORT DATE: November 2007

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-11-2007		2. REPORT TYPE Final		3. DATES COVERED 30 Oct 2005– 29 Oct 2007	
4. TITLE AND SUBTITLE TSC2 Haploinsufficiency Leads to a Mutator Phenotype				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0049	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Cheryl Walker, Ph.D. Email: CHWALKER@MDANDERSON.ORG				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M.D. Anderson Cancer Center Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Tuberous Sclerosis Complex (TSC) patients develop tumors of the brain, kidney, skin and heart upon loss of either the TSC1 or TSC2 gene, and we are interested in elucidating early molecular events that contribute to loss of TSC2 and in understanding how TSC2 heterozygosity might contribute to this process. Our lab uses the Eker rat, which possesses an inactivating retroviral insertion in one Tsc2 allele (Tsc2Ek/+), as a model to better understand how Tsc2 heterozygosity contributes to cancer susceptibility. The goal of this award was to determine whether Tsc2 haploinsufficiency generated a mutator phenotype in target tissues in vivo that possibly contributed to early events in tumorigenesis within TSC2+/- individuals and establish an in vitro model of Tsc2 haploinsufficiency. We were able to successfully establish an in vitro method of depleting Tsc2 expression, and we are performing experiments to analyze mutation frequency and spectra in vitro in the presence or absence of Tsc2 expression. In addition, our preliminary results indicate that rats heterozygous for Tsc2 have a higher mutation frequency in vivo as they age compared to wild-type rats.					
15. SUBJECT TERMS Big Blue rat, Eker rat, haploinsufficiency, mutation frequency, mutation spectra, mutator phenotype, TSC, TSC2, tuberin					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body	5
Key Research Accomplishments	7
Reportable Outcomes	7
Conclusion	7
References.....	7
Appendices	7
Supporting Data	8

Introduction

Tumors (brain, kidney, skin and heart) of Tuberous Sclerosis Complex (TSC) patients follow Knudson's 2-hit model for tumorigenesis whereby germline defects in one allele of either the *TSC1* or *TSC2* gene is accompanied by somatic inactivation of the remaining wild type allele (1,2). Our lab uses the Eker rat, which possess an inactivating retroviral insertion in one *Tsc2* allele (*Tsc2*^{Ek/+}), as a model to better understand how *Tsc2* heterozygosity contributes to cancer susceptibility (3). The Eker rat is highly susceptible to spontaneous and chemically induced renal tumors, and our lab is interested in elucidating early molecular events that contribute to loss of tuberin function and in understanding how *TSC2* heterozygosity might contribute to spontaneous and chemically induced cellular transformation and tumor progression.

The purpose of this Concept Award was to determine whether haploinsufficiency of the *Tsc2* gene generated a mutator phenotype in target tissues before the development of tumors. This could provide a mechanism for acquisition of additional genetic alterations that possibly contributed to early events in tumorigenesis in *TSC2*^{+/-} individuals. To test this hypothesis, our lab obtained a licensing agreement from Stratagene to cross Eker rats with Big Blue ratsTM that carry biallelic copies of the λ LIZ shuttle vector, producing Big Blue/Eker (BB/Ek) and Big Blue/wild type (BB/WT) F1 rats. These F1 animals permit analysis of the effect of a defective *Tsc2* allele on the mutation frequency and spectra in rats that carry the λ LIZ shuttle vector. Mutation frequencies and spectra can be analyzed using bacteriophage lytic growth to detect mutations within the cII region of λ LIZ or blue-white screening of bacterial colonies to detect mutations in the *lac* region of the λ LIZ transgene.

The scope of this project included determining whether Eker rats developed a mutator phenotype in organs prone to tumorigenesis spontaneously or in response to treatment with carcinogens. In addition, part of this project aimed to establish an *in vitro* model for *Tsc2* haploinsufficiency leading to a mutator phenotype.

Body

Aim 1: Determine whether Tsc2 haploinsufficiency results in a mutator phenotype as a result of increased oxidative damage to DNA.

Task1. Analysis of mutation frequency and mutation spectra in DNA from kidney OSOM of rats that have been treated with TGHQ (known to increase oxidative damage to kidney OSOM).

Task2. Analysis of mutation frequency and mutation spectra in DNA from kidney tissue of rats treated with KBrO₃.

Eker rats were successfully crossed with Big Blue rats that carry biallelic copies of the λ LIZ shuttle vector, generating enough F1 animals (both BB/Ek and BB/WT) to perform the treatments described in Task 1 and Task 2 of this Aim. After initially obtaining results that showed BB/Ek rats had a higher mutation frequency (as measured by bacteriophage lytic growth) than BB/WT rats after treatment with TGHQ, we were unable to reproduce these results and found that TGHQ did not have an impact on the mutation frequency of the cII region of the λ LIZ transgene in either wild-type or Eker rats that contained the λ LIZ shuttle vector. This was quite surprising, since TGHQ was previously reported to increase 8-oxo-dG levels in Eker rats (4); however, it should be noted that we never tested our F1 rats by an independent mechanism for increased ROS upon TGHQ treatment. Therefore, the research was delayed, and we requested an extension of this award (~September 2006). Since the TGHQ treatments used for detection of 8-oxo-dG were much shorter (3 days) than our treatments (2-3 weeks), we chose not to analyze these samples for signs of ROS. Instead, we analyzed genomic DNA from animals used for Task 2 by HPLC to detect 8-oxo-dG, a DNA lesion and ROS indicator. We were unable to detect an increase in 8-oxo-dG in KBrO₃-treated animals compared to control rats.

Aim 2: Determine whether the mutator phenotype is specific for tissues at risk for tumorigenicity in heterozygous individuals.

Task 1. Analysis of mutation frequency and mutation spectra using DNA from target tissues (kidney and spleen) and non-target tissues (lung and liver) in rats aged-out over one year.

Task 2. To analyze mutation frequency and spectra using DNA from target tissues (kidney and spleen) and non-target tissues (lung and liver) of BSO-treated rats.

F1 rats (both BB/EK and BB/WT) were treated as described in Task 1 and Task 2. For task 1, rats were aged to 2, 4, 8, and 12-months and then sacrificed. For task 2, two-month old rats were treated with low or high doses of BSO for three weeks, and then sacrificed. Data from these animals indicates that 8-month old Eker rats have a higher spontaneous mutation frequency in DNA isolated from kidney tissue than 8-month old wild-type rats (see Appendix, Figure 1); however, this was not observed in other non-target tissues.

Aim 3: Establish an in vitro system to explore mechanisms by which TSC2 haploinsufficiency results in a mutator phenotype in human cells.

Task 1. Analyze mutation frequency and mutation spectra using DNA from Big Blue rat fibroblast treated with Tsc2 siRNA.

Begin Task 2. Transfect HEK293 and HeLa cells with chemically synthesized TSC2 siRNA molecules and analyze repression of tuberin expression.

We tested three different chemically synthesized siRNA in Big Blue rat fibroblasts and found one chemically synthesized siRNA capable of repressing tuberin protein levels (see Appendix, Figure 2). However, no differences in spontaneous mutation frequency (within the cII region) could be detected after 3-days.

In addition, we have tested several chemically synthesized siRNA molecules for human TSC2 in HEK293 and MCF-7 cells and are also capable of repressing tuberin expression in human cell lines (data not shown), so Task 2 of this Aim has been completed. In the future it may be possible to generate stable cell lines expressing TSC2 siRNA in order to analyze mutagenesis in the human cell line system to continue these studies.

Key Research Accomplishments

- Successfully bred Big Blue and Eker rats; treated F1 progeny as described in Aims 1 and 2
- Performed phage method of mutation detection (cII region of λ LIZ transgene) for Aims 1-3
- Set up *in vitro* TSC2 haploinsufficiency system in Big Blue rat fibroblasts and human cells as described in Aim 3
- Generated preliminary data that aged Eker rats (Tsc2^{Ek/+}) have a higher mutation frequency than Tsc2^{+/+} rats.

Reportable Outcomes

N/A

Conclusion

Although we were able to cross Eker rats with Big Blue rats and successfully treat the F1 rats as described in Aims 1 and 2 and generate an *in vitro* method of depleting tuberlin expression, we were unable to reproducibly use the phage method of mutation detection (cII region of λ LIZ transgene). However, our data from Task 1 of Aim 2 (Eker rats have higher mutation frequency than wild-type rats) cause us to be optimistic that Eker rats have a higher mutation frequency than wild-type rats. For this reason, the research was delayed and we previously filed for an extension on this grant to complete these studies. We will likely have to verify our findings using both the phage method (cII mutation detection) along with the blue-white method of mutation detection (lac region of λ LIZ transgene) for future experiments before being able to definitively say whether there are differences in the mutation frequency or spectra that are due to Tsc2 haploinsufficiency.

References

1. Cheadle, J. P., Reeve, M. P., Sampson, J. R., and Kwiatkowski, D. J. (2000) *Hum Genet* **107**, 97-114
2. Hengstschlager, M., and Rosner, M. (2003) *Prog Cell Cycle Res* **5**, 43-48
3. Yeung, R. S., Xiao, G. H., Jin, F., Lee, W. C., Testa, J. R., and Knudson, A. G. (1994) *Proc Natl Acad Sci U S A* **91**, 11413-11416
4. Habib, S. L., Phan, M. N., Patel, S. K., Li, D., Monks, T. J., and Lau, S. S. (2003) *Carcinogenesis* **24**, 573-582
5. Monroe, J. J., Kort, K. L., Miller, J. E., Marino, D. R., and Skopeck, T. R. 1998. *Mutation Research*. **421**, 121-136

Appendices

N/A

Supporting Data




Figure 1. Spontaneous mutation frequency of DNA from kidney of 8-month old WT and Eker rats (n=2). The mutation frequency of DNA from WT animals fell within the normal DNA mutation frequency of $1-2 \times 10^{-5}$ (as reported by Stratagene, Inc.), but the mutation frequency of Eker rat DNA was much higher than the normal frequency.




Figure 2. Suppression of tuberin protein levels by siRNA. Three chemically synthesized TSC2 siRNAs were transfected into Big Blue rat fibroblast cells for 48-hours. Western blot analysis using an anti-tuberin antibody revealed that one of the siRNA molecules (Tsc2 siRNA-B) was capable of ablating tuberin expression. Similar results were seen at 72-hours post-transfection. A non-specific band is also shown to indicate equal loading.